160642-74-0

Upstream product

• 22118-09-8 2-bromoacetyl chloride 
• 160642-45-5 8-[3-(N-glycyl-N-methylamino)-2,6-dichlorobenzyloxy]-3-bromo-2-methylimidazo[1,2-a]pyridine 
• 5866-97-7 2,6-dichloro-3-nitrobenzaldehyde 
• 160647-01-8 2,6-Dichloro-3-nitrobenzyl alcohol 
• 149976-78-3 2,6-dichloro-1-methanesulfonyloxymethyl-3-nitrobenzene 
• 160647-05-2 8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine 
• 160641-64-5 3-bromo-8-[2,6-dichloro-3-(N-methyl-N-phthalimidoacetylamino)benzyloxy]-2-methylimidazo[1,2-a]pyridine 
• 160642-16-0 N-[3-(3-Bromo-2-methyl-imidazo[1,2-a]pyridin-8-yloxymethyl)-2,4-dichloro-phenyl]-2-(1,3-dioxo-1,3-dihydro-isoindol-2-yl)-acetamide 
• 160641-39-4 3-bromo-8-(2,6-dichloro-3-nitrobenzyloxy)-2-methylimidazo[1,2-a]pyridine 

Relevant academic research and scientific papers

A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework

A novel class of potent, selective, and orally active non-peptide bradykinin (BK) B2 receptor antagonists were designed and synthesized starting from 8-benzyloxyimidazo[1,2-α]pyridine derivative 2. The unique screening lead (2) was discovered b